Moleculin completes enrollment in Part A of pivotal MIRACLE AML trial, eyes Q1 2027 dataNov 16Quarterly updateMoleculin Biotech, Inc.
Cullinan reports Q3 2026 results, flags December CLN-978 data and zipalertinib NDA progressNov 10Quarterly updateBlossomHill TherapeuticsCLN-978
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Moleculin's Annamycin AML data accepted for presentation at ASH 2026Nov 4PublicationMoleculin Biotech, Inc.
Vanderbilt trial tests intrathecal cytarabine for ICANS after CAR T; Gilead is collaboratorOct 2Trial updatecytarabineGilead Sciences
Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screeningSep 29Trial updateMoleculin Biotech, Inc.
Roswell Park's Phase II CPX-351 trial in younger secondary AML patients marked completedAug 31Trial updateJazz Pharmaceuticals
Moleculin reports positive interim MIRACLE data, keeps trial timeline on trackAug 14Quarterly updateMoleculin Biotech, Inc.
Vanderbilt registers Phase 2 Lazarus trial testing IT therapy to prevent ICANS after CAR TAug 13Trial updateGilead Sciences
Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trialJul 31Clinical readoutMoleculin Biotech, Inc.venetoclax